Realbotix is rebranding its humanoid lineup as Series 1, pitching the move as a step toward commercialized 'physical AI.' The flagship of that line, Echo, ships with a face, a voice, and a price tag of $11,950 — plus a monthly subscription fee to keep its personality switched on, turning a one-time robot purchase into a recurring bill.
Boston Dynamics has quietly rebuilt Atlas's supply chain around South Korean parts makers led by parent company Hyundai's Mobis unit, positioning itself for an order of up to 10,000 units. The move comes as the company faces pointed questions about whether it can keep pace with Tesla's Optimus and a crowded field of Chinese humanoid manufacturers.
At a Paris event flanked by robot ducks, Jensen Huang made the case for Europe's AI ambitions while Nvidia unveiled its Hyperion platform as the backbone for a wave of European robotaxi and safe-vehicle development. The announcement landed alongside news that Lucid will put 25,000 Bolt vehicles on the road as robotaxis running Nvidia's self-driving software, underscoring how central the chipmaker has become to the autonomous vehicle supply chain on both sides of the Atlantic.
Boston Dynamics is expanding its industrial robotics push on two fronts: opening a training center at Hyundai's Georgia plant to prepare Atlas humanoids for a rollout of 25,000 units across the automaker's factories by decade's end, and releasing Spot 5.2, an upgraded quadruped that ties enterprise software and scattered AI tools into a single stream of site intelligence for autonomous inspections. Together the moves signal the company's ambition to put both legged humanoids and its established Spot line to work on the same shop floors.
Eka, a physical AI startup drawing praise from researchers for its underlying model, has reached a $1.45 billion valuation. The jump coincides with a combined $380 million funding round that Eka raised alongside fellow physical AI company Arda, underscoring investor appetite for robotics-focused AI amid a string of recent eye-catching valuations in the space.
Days before becoming the first general-purpose robotics company to list on mainland China's stock market, Unitree unveiled a new high-speed robot dubbed 'Superman.' The timing underscores what WSJ frames as a broader test of investor appetite for physical AI hardware in China, with Unitree's legged and humanoid robots serving as the industry's flagship bet.
Unitree is developing an AI system that lets its humanoid robots learn and refine their own performance without constant human reprogramming, part of a broader push toward autonomous skill-building. Founder Wang Xingxuan says the industry could hit its own 'ChatGPT moment' by 2027, though he admits that leap in capability won't automatically translate into commercial deployment. Together, the items sketch a company racing ahead on the technical frontier while staying candid about the harder business of turning clever robots into viable products.
Unitree's G1 humanoid, a four-foot robot piloted by Polish developers, has racked up over a billion views and become an unlikely social-media celebrity. Yet a research note tied to Unitree's IPO cautions that the buzz outpaces the business: the humanoid robot market remains in its early innings despite the company's rapid growth.
As AgiBot and fellow humanoid robot makers post revenue growth that's outpacing even their VC hype cycle, the Chinese firm used its 2026 Innovation Day to unveil Worken, a system meant to quantify how productive a robot actually is on the job. Taken together, the news suggests AgiBot is trying to move the conversation from venture funding rounds to measurable output — the kind of proof point that could justify those growth numbers.
Unitree, the Chinese robotics firm whose founder's relentless cost-cutting has made it the price leader in humanoid robots, is having a mixed news day. One story credits that frugality with the company's dominant market position; another shows one of its lab robots throwing spinning kicks that nearly connected with an engineer's face during testing, a jarring reminder that cheap and controlled aren't always the same thing.